



Published in final edited form as:

Cancer Causes Control. 2011 February ; 22(2): 301–309. doi:10.1007/s10552-010-9698-z.

MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers

Kaori Shima,

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Teppei Morikawa,

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Yoshifumi Baba,

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Katsuhiko Nosh,

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Maiko Suzuki,

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Mai Yamauchi,

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Marika Hayashi,

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Edward Giovannucci,

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, MA, USA

Charles S. Fuchs, and

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Shuji Ogino

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 44 Binney St., Room JF-215C, Boston, MA 02115, USA

Correspondence to: Shuji Ogino, shuji_ogino@dfci.harvard.edu.

Kaori Shima, Teppei Morikawa and Yoshifumi Baba contributed equally.

Conflicts of interest No conflicts of interest exist.

Shuji Ogino: shuji_ogino@dfci.harvard.edu

Abstract

Objective—*O*⁶-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme. *MGMT* promoter hypermethylation and epigenetic silencing often occur as early events in carcinogenesis. However, prognostic significance of *MGMT* alterations in colorectal cancer remains uncertain.

Methods—Utilizing a database of 855 colon and rectal cancers in two prospective cohort studies (the Nurses' Health Study and the Health Professionals Follow-up Study), we detected *MGMT* promoter hypermethylation in 325 tumors (38%) by MethyLight and loss of MGMT expression in 37% (247/672) of tumors by immunohistochemistry. We assessed the CpG island methylator phenotype (CIMP) using eight methylation markers [*CACNA1G*, *CDKN2A* (p16), *CRABP1*, *IGF2*, *MLH1*, *NEUROG1*, *RUNX3*, and *SOCS1*], and LINE-1 (L1) hypomethylation, TP53 (p53), and microsatellite instability (MSI).

Results—*MGMT* hypermethylation was not associated with colorectal cancer-specific mortality in univariate or multivariate Cox regression analysis [adjusted hazard ratio (HR) = 1.03; 95% confidence interval (CI), 0.79–1.36] that adjusted for clinical and tumor features, including CIMP, MSI, and *BRAF* mutation. Similarly, MGMT loss was not associated with patient survival. MGMT loss was associated with G>A mutations in *KRAS* ($p = 0.019$) and *PIK3CA* ($p = 0.0031$).

Conclusions—Despite a well-established role of MGMT aberrations in carcinogenesis, neither *MGMT* promoter methylation nor MGMT loss serves as a prognostic biomarker in colorectal cancer.

Keywords

Colon cancer; *MGMT*; Hypermethylation; Epigenetics; Clinical outcome

Introduction

The *O*⁶-methylguanine-DNA methyltransferase (*MGMT*) gene encodes DNA repair protein and is frequently inactivated in colorectal cancer [1, 2]. Polymorphisms in *MGMT* have been associated with colorectal cancer risk [3, 4], and *MGMT* promoter methylation in normal colonic mucosa might be a predisposing factor for cancer as a field effect and an early event in colorectal carcinogenesis [5, 6]. *MGMT* promoter methylation and loss of expression have been associated with G>A mutations in a variety of genes such as *KRAS*, *PIK3CA*, *TP53*, and *APC* [7–11]. Jass [12] proposed the molecular classification based on CIMP, MSI, *BRAF*, *KRAS*, and *MGMT* promoter methylation, indicating that *MGMT* methylation is one of the key molecular alterations in colorectal cancer. In addition, *MGMT* has potential as a therapeutic target in human cancer [13, 14]. Collectively, it is of interest to examine a prognostic role of *MGMT* alteration as a tumor biomarker. In brain tumors and B-cell lymphoma, *MGMT* methylation or loss of MGMT has been associated with poor prognosis [15–17]. However, prognostic significance of *MGMT* alteration in colorectal cancer remains inconclusive due to limited statistical power of all previous studies (Table 1; all $n < 200$) [18–22].

In this study using the database of a large number ($n = 855$) of stage I–IV colorectal cancers, we examined the prognostic effect of *MGMT* promoter methylation and loss of expression. Since we concurrently assessed other molecular variables including LINE-1 hypomethylation, MSI, CIMP, and mutation in *KRAS*, *BRAF*, and *PIK3CA*, we could evaluate the prognostic effect of *MGMT* alteration after controlling for those potential confounders.

Materials and methods

Study population

We utilized the database of two prospective cohort studies, the Nurses' Health Study ($n = 121,701$ women followed since 1976) [23] and the Health Professionals Follow-up Study ($n = 51,529$ men followed since 1986) [23]. Participants have been sent biennial questionnaires to update information on potential risk factors and to identify newly diagnosed cancers in themselves and their first-degree relatives. We collected paraffin-embedded tumor tissue blocks of incident colorectal cancers from hospitals where participants with colorectal cancer underwent tumor resection. Hematoxylin and eosin (H&E)-stained tissue sections from all colorectal cancer cases were confirmed by a pathologist (S.O.) unaware of other data. The tumor grade was categorized as low versus high (>50 vs. 50% gland formation). Positive family history of colorectal cancer was defined as the presence of colorectal cancer in any first-degree relative. We excluded cases that were preoperatively treated. Based on the availability of adequate follow-up and tumor tissue data, 855 stage I–IV colorectal cancer cases diagnosed up to 2002 were included. Patients were observed until death or June 2009, whichever came first. This study was approved by the Human Subjects Committees at Harvard School of Public Health and Brigham and Women's Hospital.

Pyrosequencing of *KRAS*, *BRAF*, and *PIK3CA*, and microsatellite instability (MSI) analysis

Genomic DNA was extracted from paraffin-embedded tissue. PCR and pyrosequencing targeted for *KRAS* (codons 12 and 13) [24], *BRAF* (codon 600) [25], and *PIK3CA* (exons 9 and 20) [11] were performed. Microsatellite instability (MSI) analysis was performed using 10 micro-satellite markers (D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67, and D18S487) [26]. MSI-high was defined as the presence of instability in 30% of the markers and MSI-low/microsatellite stable (MSS) as instability in 0–29% of markers [26].

Methylation analyses for CpG islands and LINE-1

Sodium bisulfite treatment and subsequent real-time PCR were performed to quantify promoter methylation in *MGMT* and eight other CpG islands (*CACNA1G*, *CDKN2A*, *CRABP1*, *IGF2*, *MLH1*, *NEUROG1*, *RUNX3*, and *SOC3*) [27, 28]; the latter eight markers have been shown to be specific for CIMP [29]. CIMP-high was defined as the presence of 6/8 methylated markers, CIMP-low as the presence of 1/8–5/8 methylated markers, and CIMP-0 as the absence (0/8) of methylated markers [30]. We defined and validated the cut point for *MGMT* promoter methylation positivity (percentage of methylated reference, or PMR > 4) as previously described [31]. LINE-1 methylation levels were quantified by PCR-pyrosequencing [32, 33].

Immunohistochemical analysis

Immunohistochemical methods for *MGMT* and TP53 (p53) were previously described [26], and expression patterns were interpreted by a pathologist (S.O.) unaware of other data. In agreement studies, a random selection of more than 100 cases for each marker was interpreted by a second pathologist unaware of other data (*MGMT* by K.S.; TP53 by K.N.). The concordance between the two observers (both $p < 0.0001$) was 0.86 for *MGMT* ($\kappa = 0.70$) and 0.87 for TP53 ($\kappa = 0.75$), indicating substantial agreement. The concordance between *MGMT* methylation and loss of *MGMT* was 81% ($\kappa = 0.59$).

Statistical analysis

We used SAS program (Version 9.1, SAS Institute, Cary, NC) for all statistical analysis. All p values were two-sided, and significance level was set at $p = 0.05$. The chi-square test (or

Fisher's exact test) was performed for categorical variables. For survival analysis, the Kaplan–Meier method and log-rank test were used. For analyses of colorectal cancer–specific mortality, deaths as a result of causes other than colorectal cancer were censored. To control for confounding, we used multivariate stage-matched (stratified) Cox proportional hazard models to compute hazard ratio (HR) of death according to *MGMT* status. To avoid residual confounding and overfitting, disease stage (I, IIA, IIB, IIIA, IIIB, IIIC, IV, unknown) was used as a stratifying variable, utilizing the “strata” option in the SAS “proc phreg” command. The multivariate model initially included age at diagnosis (continuous), sex, year of diagnosis (continuous), BMI (<30 vs. 30 kg/m²), family history of colorectal cancer (present vs. absent), tumor location (proximal colon vs. distal colon vs. rectum), tumor grade (low vs. high), MSI (high vs. low/MSS), CIMP (high vs. low vs. CIMP-0), LINE-1 methylation (continuous), and *BRAF*. A backward elimination with a threshold of $p = 0.20$ was used to select variables in the final model. For cases with missing information in any of the categorical variables [tumor location (0.9%), tumor grade (0.5%), MSI (3.0%), *BRAF* (4.8%)], we included those cases in a majority category of a given covariate to avoid overfitting. We confirmed that excluding cases with missing information in any of the covariates did not substantially alter results (data not shown). An interaction was assessed by including the cross product of the *MGMT* methylation (or *MGMT* loss) variable and another variable of interest (without data-missing cases) in a multivariate model, and the Wald test was performed. A p value for statistical significance was adjusted for multiple hypothesis testing to $p = 0.0029$ ($=0.05/17$) by Bonferroni correction.

In addition, we constructed multivariate logistic regression analysis model to assess the independent effect of *MGMT* loss on G>A mutations in *KRAS* or *PIK3CA* (as a binary outcome variable). The model initially included age at diagnosis (continuous), sex, year of diagnosis (continuous), BMI (<30 vs. 30 kg/m²), family history of colorectal cancer (present vs. absent), tumor location (proximal vs. distal), MSI (high vs. low/MSS), CIMP (high vs. low/0), LINE-1 methylation (continuous), and *MGMT* loss, and a backward elimination with a threshold of $p = 0.20$ was done to select variables in the final model.

Results

***MGMT* methylation and loss of *MGMT* in colorectal cancer**

MGMT promoter methylation was detected in 325 (38%) of 885 tumors, and loss of *MGMT* was detected in 247 (37%) of 672 tumors. There was a significant association between *MGMT* promoter methylation and CIMP status ($p < 0.0001$). Loss of *MGMT* was significantly associated with *PIK3CA* mutation ($p = 0.0031$) and inversely associated with TP53 expression ($p = 0.0004$; Table 2).

MGMT* methylation/loss and G>A mutations in *KRAS* and *PIK3CA

Because functional loss of *MGMT* may contribute to G>A mutations [7–11], we examined the relations between *MGMT* methylation (or loss) and G>A mutations in *KRAS* and *PIK3CA* (Table 2). *MGMT* loss was significantly associated with G>A mutations in *KRAS* ($p = 0.019$) and *PIK3CA* ($p = 0.0031$) (by a priori hypothesis testing), while *MGMT* methylation was not. In multivariate logistic regression analysis to assess independent effect of *MGMT* loss on G>A mutations, *MGMT* loss remained significantly associated with G>A mutations in *KRAS* (adjusted OR, 1.58; 95% CI, 1.07–2.34; $p = 0.021$) and *PIK3CA* (adjusted OR, 2.55; 95% CI, 1.40–4.68; $p = 0.0024$).

***MGMT* methylation, loss of *MGMT*, and survival of patients with colorectal cancer**

Among the 855 patients, there were 415 deaths including 234 colorectal cancer–specific deaths. The median follow-up time for censored patients was 13.0 years. For either

colorectal cancer-specific or overall mortality, *MGMT* methylation was not significantly associated with patient outcome in log-rank test, or univariate or multivariate stage-matched Cox regression analysis (Table 3, Fig. 1). Likewise, loss of *MGMT* was not significantly associated with colorectal cancer-specific or overall mortality in univariate or multivariate stage-matched analysis (Table 3, Fig. 1).

We analyzed the prognostic effect of *MGMT* methylation or loss of *MGMT* in colon cancer and rectal cancer separately, since clinical management for patients with colon cancer differ from that for patients with rectal cancer. *MGMT* methylation (or *MGMT* loss) was not significantly associated with colorectal cancer-specific or overall mortality in either patients with colon cancer or rectal cancer (Table 3).

There was no significant modifying effect on the prognostic influence of *MGMT* methylation (or *MGMT* loss) by Table 2 Clinical and molecular characteristics in colorectal cancer with *MGMT* promoter methylation/loss of *MGMT* any of the other variables including sex, age, year of diagnosis, BMI, family history of colorectal cancer, tumor location, stage, tumor grade, CIMP, MSI, *BRAF*, *KRAS*, *PIK3CA*, LINE-1 methylation, and TP53 (all $P_{\text{interaction}} > 0.02$).

Discussion

We conducted this study to examine whether *MGMT* promoter methylation or loss of expression in colorectal cancer has any prognostic role. This question has remained inconclusive due to limited statistical power of all previous studies on this topic [18–22]. Given the crucial roles of *MGMT* aberrations in colorectal carcinogenesis or a potential use of *MGMT* as a therapeutic target in human cancer, the assessment of *MGMT* alteration (i.e., *MGMT* promoter methylation or loss of *MGMT*) and clinical outcome using a large number of cancers is needed. Utilizing the database of 855 clinically and molecularly annotated colorectal cancers in the two large prospective cohort studies, we found that *MGMT* alteration was not associated with patient prognosis in colorectal cancer. In addition, we assessed the prognostic effect of *MGMT* promoter methylation (or *MGMT* loss), controlling for other molecular features, including CIMP, MSI, and *BRAF* mutation, all of which have been documented to be critical in colorectal carcinogenesis.

Studying molecular variants and somatic changes is important in cancer research [34–42]. Recent studies have shown that *MGMT* promoter polymorphism (rs16906252) is associated with *MGMT* methylation in colorectal cancer [43], in normal colorectal mucosa [44], and in peripheral blood cells from normal individuals [45]. Epigenetic silencing of *MGMT* by promoter methylation in normal colonic mucosa may be a predisposing factor for cancer as a field effect and an early event in colorectal carcinogenesis [5, 6]. In addition, *MGMT* methylation might be a valuable biomarker in plasma for early detection of colorectal cancer [46].

Studies on colorectal cancer have shown that *MGMT* methylation is associated with *MGMT* loss [5, 6, 47]. In agreement with these studies [5, 6, 47], our current study showed a good concordance (81%, $\kappa = 0.59$, $p < 0.0001$) between *MGMT* methylation and *MGMT* loss. *MGMT* methylation and loss of *MGMT* were not perfectly correlated perhaps due to a few reasons. First, loss of *MGMT* expression may be caused not only by promoter methylation but also by other mechanisms such as a gene deletion or mutation. Second, in rare cases, promoter methylation may be present in only one *MGMT* allele, and the *MGMT* protein may be expressed from the second allele. Third, there may be other molecules (such as miRNA) that may downregulate *MGMT*.

MGMT promoter methylation or loss of expression in colorectal cancer has been associated with G>A mutations in *KRAS* [7, 9, 10, 44, 48], *TP53* [8, 9], and *PIK3CA* [11]. Our current study is the first one to perform multivariate analysis and show that *MGMT* loss is associated with G>A mutations in *KRAS* and *PIK3CA*, independent of potential confounders. Thus, our current study supports the concept that loss of *MGMT* contributes to G>A mutations of *KRAS* and *PIK3CA*.

Previous studies [18–22] have shown no prognostic significance of *MGMT* methylation (or loss of *MGMT*) in colorectal cancers (Table 1). These previous studies [18–22] on prognostic significance of *MGMT* methylation (or *MGMT* loss) are limited by low statistical power ($n < 200$). In contrast to the prior studies [18–22], our study examined both *MGMT* promoter methylation and loss of *MGMT* expression in a much larger cohort of colorectal cancers. In the current study, *MGMT* methylation was found in 38% of colorectal cancer. Previous studies [18–22] have shown a large variation in the frequency of *MGMT* promoter methylation (21–61%; Table 1). This variation might be caused by differences in study samples and/or methylation detection methods (MSP vs. quantitative MethyLight vs. Pyrosequencing) and might also be in part due to a chance variation in the small studies.

With regard to the predictive role of *MGMT* aberrations, Braun et al. [34] examined a predictive role of loss of *MGMT* expression (among other markers) in 1,125 patients with metastatic colorectal cancer who underwent different chemotherapy treatment arms (fluorouracil vs. fluorouracil/irinotecan vs. fluorouracil/oxaliplatin) and found no predictive role of *MGMT* aberrations.

There are limitations in this study. For example, data on cancer treatment were limited. Nonetheless, it is unlikely that chemotherapy use substantially differed according to *MGMT* status in tumor, since such data were unavailable for treatment decision making. In addition, our multivariate survival analysis adjusted for disease stage as finely as I, IIA, IIB, IIIA, IIIB, IIIC, IV on which treatment decision making was mostly based. As another limitation, beyond cause of mortality, data on cancer recurrences were unavailable in these cohort studies. Nonetheless, colorectal cancer-specific survival might be a reasonable surrogate of colorectal cancer-specific outcome.

There are advantages in utilizing the database of the two prospective cohort studies, the Nurses' Health Study and the Health Professionals Follow-up Study, to examine prognostic significance of tumor biomarkers. Anthropometric measurements, family history, cancer staging, and other clinical, pathologic, and tumoral molecular data were prospectively collected, blinded to patient outcome. Cohort participants who developed cancer were treated at hospitals throughout the United States and thus more representative colorectal cancers in the US population than patients in one to a few academic hospitals. There were no demographic difference between cases with tumor tissue analyzed and those without tumor tissue analyzed [23]. Finally, our rich tumor database enabled us to simultaneously assess pathologic and tumoral molecular correlates and control for confounding by a number of tumoral molecular alterations.

In conclusion, our findings suggest that *MGMT* promoter methylation or loss of expression is not a prognostic biomarker in colorectal cancer, despite its well-established role in carcinogenesis.

Acknowledgments

We deeply thank the Nurses' Health Study and Health Professionals Follow-up Study cohort participants who have generously agreed to provide us with biological specimens and information through responses to questionnaires, and hospitals and pathology departments throughout the United States for providing us with medical records and

tumor tissue specimens. This work was supported by U.S. National Institute of Health (NIH) grants P01 CA87969 (to SE Hankinson), P01 CA55075 (to WC Willett), P50 CA127003 (to CSF), K07 CA122826 (to SO), and R01 CA151993 (to SO), and in part by grants from the Bennett Family Fund and from the Entertainment Industry Foundation National Colorectal Cancer Research Alliance. Y.B. was supported by a fellowship grant from the Uehara Memorial Foundation. K.N. and M.S. were supported by fellowship grants from the Japan Society for Promotion of Science. The content is solely the responsibility of the authors and does not necessarily represent the official views of NCI or NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abbreviations

BMI	Body mass index
CI	Confidence interval
CIMP	CpG island methylator phenotype
HR	Hazard ratio
MGMT	O ⁶ -methylguanine-DNA methyltransferase
MSI	Microsatellite instability
MSS	Microsatellite stable
OR	Odds ratio

References

- Asaka S, Arai Y, Nishimura Y, et al. Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. *Carcinogenesis*. 2009; 30:494–499. [PubMed: 19147861]
- Gonzalo V, Lozano JJ, Munoz J, et al. Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. *PLoS One*. 2010; 5:e8777. [PubMed: 20098741]
- Tranah GJ, Bugni J, Giovannucci E, et al. O6-methylguanine-DNA methyltransferase Leu84Phe and Ile143Val polymorphisms and risk of colorectal cancer in the nurses' Health Study and Physicians' health study (United States). *Cancer Causes Control*. 2006; 17:721–731. [PubMed: 16633920]
- Zhong Y, Huang Y, Huang Y, et al. Effects of O6-methylguanine-DNA methyltransferase (MGMT) polymorphisms on cancer: a meta-analysis. *Mutagenesis*. 2010; 25:83–95. [PubMed: 19892775]
- Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. *J Natl Cancer Inst*. 2005; 97:1330–1338. [PubMed: 16174854]
- Nagasaka T, Goel A, Notohara K, et al. Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. *Int J Cancer*. 2008; 122:2429–2436. [PubMed: 18240147]
- Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. *Cancer Res*. 2000; 60:2368–2371. [PubMed: 10811111]
- Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. *Cancer Res*. 2001; 61:4689–4692. [PubMed: 11406538]
- Halford S, Rowan A, Sawyer E, Talbot I, Tomlinson I. O(6)-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions. *Gut*. 2005; 54:797–802. [PubMed: 15888787]
- Ogino S, Kawasaki T, Kirkner GJ, et al. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. *Gut*. 2007; 56:1564–1571. [PubMed: 17339237]

11. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. *Neoplasia*. 2008; 10:534–541. [PubMed: 18516290]
12. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. *Histopathology*. 2007; 50:113–130. [PubMed: 17204026]
13. Hegi ME, Sciuscio D, Murat A, Levivier M, Stupp R. Epigenetic deregulation of DNA repair and its potential for therapy. *Clin Cancer Res*. 2009; 15:5026–5031. [PubMed: 19671858]
14. Watson AJ, Sabharwal A, Thorncroft M, et al. Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. *Clin Cancer Res*. 2010; 16:743–749. [PubMed: 20068091]
15. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. *J Clin Oncol*. 2008; 26:4189–4199. [PubMed: 18757334]
16. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC brain tumor group study 26951. *J Clin Oncol*. 2009; 27:5881–5886. [PubMed: 19901104]
17. Esteller M, Gaidano G, Goodman SN, et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. *J Natl Cancer Inst*. 2002; 94:26–32. [PubMed: 11773279]
18. Nagasaka T, Sharp GB, Notohara K, et al. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. *Clin Cancer Res*. 2003; 9:5306–5312. [PubMed: 14614014]
19. Krtolica K, Krajnovic M, Usaj-Knezevic S, et al. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. *World J Gastroenterol*. 2007; 13:1187–1194. [PubMed: 17451198]
20. Chen SP, Chiu SC, Wu CC, et al. The association of methylation in the promoter of APC and MGMT and the prognosis of Taiwanese CRC patients. *Genet Test Mol Biomarkers*. 2009; 13:67–71. [PubMed: 19309276]
21. Kim JC, Choi JS, Roh SA, et al. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. *Ann Surg Oncol*. 2010; 17:1767–1776. [PubMed: 20077021]
22. Kohonen-Corish MR, Daniel JJ, Chan C, et al. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. *J Clin Oncol*. 2005; 23:2318–2324. [PubMed: 15800322]
23. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. *N Engl J Med*. 2007; 356:2131–2142. [PubMed: 17522398]
24. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. *J Mol Diagn*. 2005; 7:413–421. [PubMed: 16049314]
25. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. *J Mol Diagn*. 2006; 8:582–588. [PubMed: 17065427]
26. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. *Mod Pathol*. 2006; 19:59–68. [PubMed: 16118624]
27. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. *Gut*. 2006; 55:1000–1006. [PubMed: 16407376]
28. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. *Nat Genet*. 2006; 38:787–793. [PubMed: 16804544]
29. Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. *J Mol Diagn*. 2007; 9:305–314. [PubMed: 17591929]
30. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. *PLoS One*. 2008; 3:e3698. [PubMed: 19002263]

31. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. *J Mol Diagn.* 2006; 8:209–217. [PubMed: 16645207]
32. Ogino S, Kawasaki T, Nosho K, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. *Int J Cancer.* 2008; 122:2767–2773. [PubMed: 18366060]
33. Irahara N, Nosho K, Baba Y, et al. Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. *J Mol Diagn.* 2010; 12:177–183. [PubMed: 20093385]
34. Braun MS, Richman SD, Quirke P, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. *J Clin Oncol.* 2008; 26:2690–2698. [PubMed: 18509181]
35. Weijenberg MP, Luchtenborg M, de Goeij AF, et al. Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes. *Cancer Causes Control.* 2007; 18:865–879. [PubMed: 17636402]
36. Samowitz WS, Curtin K, Wolff RK, et al. Microsatellite instability and survival in rectal cancer. *Cancer Causes Control.* 2009; 20:1763–1768. [PubMed: 19669908]
37. Berndt SI, Huang WY, Yeager M, et al. Genetic variants in frizzled-related protein (FRZB) and the risk of colorectal neoplasia. *Cancer Causes Control.* 2009; 20:487–490. [PubMed: 19067193]
38. Tsilidis KK, Helzlsouer KJ, Smith MW, et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. *Cancer Causes Control.* 2009; 20:1739–1751. [PubMed: 19760027]
39. Iglesias D, Nejda N, Azcoita MM, et al. Effect of COX2–765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. *Cancer Causes Control.* 2009; 20:1421–1429. [PubMed: 19468846]
40. Figueiredo JC, Levine AJ, Lee WH, et al. Genes involved with folate uptake and distribution and their association with colorectal cancer risk. *Cancer Causes Control.* 2009; 21:597–608. [PubMed: 20037791]
41. Van Guelpen B, Dahlin AM, Hultdin J, et al. One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case-referent study. *Cancer Causes Control.* 2010; 21:557–566. [PubMed: 20012180]
42. Feik E, Baierl A, Hieger B, et al. Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. *Cancer Causes Control.* 2009; 21:91–97. [PubMed: 19784788]
43. Ogino S, Hazra A, Tranah GJ, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. *Carcinogenesis.* 2007; 28:1985–1990. [PubMed: 17621591]
44. Hawkins NJ, Lee JH, Wong JJ, et al. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. *Mod Pathol.* 2009; 22:1588–1599. [PubMed: 19734844]
45. Candiloro IL, Dobrovic A. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. *Cancer Prev Res (Phila Pa).* 2009; 2:862–867.
46. Lee BB, Lee EJ, Jung EH, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. *Clin Cancer Res.* 2009; 15:6185–6191. [PubMed: 19773381]
47. Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. *Cancer Res.* 2001; 61:827–830. [PubMed: 11221863]
48. de Vogel S, Weijenberg MP, Herman JG, et al. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. *Ann Oncol.* 2009; 20:1216–1222. [PubMed: 19164452]




Fig. 1. Kaplan–Meier curves for colorectal cancer–specific survival (*upper panel*) and overall survival (*lower panel*), according to *MGMT* promoter methylation (**a**, **b**) or loss of *MGMT* (**c**, **d**) in colorectal cancer

Table 1

Studies on prognostic significance of *MGMT* methylation (top) or loss of *MGMT* (bottom) in colorectal cancer

Ref.	Authors (year)	Sample size	No. of events		Disease stage	Chemotherapy	<i>MGMT</i> methylation (vs. no methylation) or loss of <i>MGMT</i> (vs. expression)				Note		
			OS	CS			Methylated (<i>MGMT</i> -lost) cases (%)	<i>p</i> value by log-rank test	OS univariate HR (95% CI)	<i>p</i> value by univariate model		OS multi-variate HR (95% CI)	<i>p</i> value by multi-variate model
<i>MGMT</i> methylation													
[18]	Nagasaka et al. (2003)	90	-	-	Dukes A-D	Fluoro-pyrimidines	MSP	29	-	-	1.30 ^a (0.27-6.47)	NS	
[19]	Krtolica et al. (2007)	47	-	-	Dukes A-D	-	MSP	43	NS	NS	-	NS	
[20]	Chen et al. (2009)	117	-	-	Dukes A-D	Adjuvant chemotherapy	MSP	61	-	-	1.33 (0.61-2.92)	<i>p</i> = 0.47	
[21]	Kim et al. (2010)	131	-	-	I-IV	Adjuvant chemotherapy	Pyro-sequencing	21	-	NS	-	NS	
<i>Loss of MGMT</i>													
[22]	Kohonen-Conish et al. (2005)	178	141	-	Dukes C	Adjuvant chemotherapy	IHC	22	<i>p</i> = 0.55	-	-	-	
	Current study	672	313	170	I-IV	-	IHC	37	<i>p</i> = 0.54	0.94 (0.75-1.18)	<i>p</i> = 0.59	1.11 (0.87-1.41)	<i>p</i> = 0.39

CI confidence interval, *CIMP*CpG island methylator phenotype, *CS* colorectal cancer-specific survival, HR, hazard ratio, *IHC* immunohistochemistry, *MSP* methylation-specific PCR, *NS* not significant, *OS* overall survival, *MSP* quantitative methylation-specific PCR

^aPatients with unmethylated *MGMT* promoters at a 1.3-fold increased risk of death

Table 2
Clinical and molecular characteristics in colorectal cancer with *MGMT* promoter methylation/loss of *MGMT*

Clinical or molecular feature	All cases		<i>MGMT</i> promoter methylation		<i>MGMT</i> status		<i>p</i> value
	(-)	(+)	Expressed	Lost	Expressed	Lost	
Total <i>n</i>	855	325	425	247			
Sex							0.71
Male (HPFS)	367 (43%)	131 (40%)	173 (41%)	97 (39%)			
Female (NHS)	488 (57%)	194 (60%)	252 (59%)	150 (61%)			
Mean age ± SD	66.2 ± 8.4	66.3 ± 8.1	66.3 ± 8.4	65.9 ± 7.9			0.60
Body mass index (BMI)							0.093
<30 kg/m ²	714 (83%)	276 (85%)	347 (82%)	214 (87%)			
30 kg/m ²	141 (17%)	49 (15%)	78 (18%)	33 (13%)			
Family history of colorectal cancer in any 1st degree relative							0.28
Absent	646 (76%)	250 (77%)	319 (75%)	176 (71%)			
Present	209 (24%)	75 (23%)	106 (25%)	71 (29%)			
Year of diagnosis							0.031
Prior to 1995	400 (47%)	155 (48%)	182 (43%)	127 (51%)			
1995–2004	455 (53%)	170 (52%)	243 (57%)	120 (49%)			
Tumor location							0.014
Proximal colon (cecum to transverse)	381 (45%)	142 (44%)	197 (47%)	108 (44%)			
Distal colon (splenic flexure to sigmoid)	273 (32%)	105 (33%)	125 (30%)	96 (39%)			
Rectum	192 (23%)	75 (23%)	100 (24%)	40 (16%)			
Disease stage							0.70
I	199 (23%)	75 (23%)	94 (22%)	57 (23%)			
II	259 (30%)	103 (32%)	133 (31%)	77 (31%)			
III	228 (27%)	82 (25%)	110 (26%)	69 (28%)			
IV	102 (12%)	37 (11%)	57 (13%)	24 (9.7%)			
Unknown	67 (7.8%)	28 (8.6%)	31 (7.3%)	20 (8.1%)			
Tumor grade							0.23
Low	771 (91%)	291 (90%)	389 (92%)	220 (89%)			
High	79 (9.3%)	32 (9.9%)	33 (7.8%)	26 (11%)			

Clinical or molecular feature	All cases		MGMT promoter methylation		MGMT status		p value
	(-)	(+)	(-)	(+)	Expressed	Lost	
MSI status							0.21
MSS/MSI-low	705 (85%)	263 (83%)	442 (87%)	263 (83%)	361 (86%)	201 (83%)	
MSI-high	124 (15%)	54 (17%)	70 (13%)	54 (17%)	57 (14%)	42 (17%)	
CIMP status							0.0077
CIMP-0	399 (47%)	119 (37%)	280 (53%)	119 (37%)	218 (51%)	96 (39%)	
CIMP-low	325 (38%)	141 (43%)	184 (35%)	141 (43%)	145 (34%)	107 (43%)	
CIMP-high	131 (15%)	65 (20%)	66 (12%)	65 (20%)	62 (15%)	44 (18%)	
KRAS mutation							0.019
(-)	529 (63%)	197 (62%)	332 (64%)	197 (62%)	281 (67%)	136 (56%)	
Non G>A mutation	185 (22%)	74 (23%)	111 (22%)	74 (23%)	86 (20%)	66 (27%)	
G>A	121 (14%)	48 (15%)	73 (14%)	48 (15%)	53 (13%)	41 (17%)	
BRAF mutation							0.11
(-)	703 (87%)	269 (86%)	434 (86%)	269 (86%)	347 (84%)	209 (89%)	
(+)	111 (13%)	43 (14%)	68 (14%)	43 (14%)	64 (16%)	26 (11%)	
PIK3CA mutation							0.0031
(-)	627 (84%)	230 (81%)	397 (86%)	230 (81%)	335 (88%)	167 (79%)	
Non G>A mutation	53 (7.1%)	27 (9.5%)	26 (5.7%)	27 (9.5%)	23 (6.1%)	16 (7.6%)	
G>A	64 (8.6%)	28 (9.8%)	36 (7.8%)	28 (9.8%)	21 (5.5%)	28 (13%)	
Mean LINE-1 methylation (%) ± SD	61.4 ± 9.5	61.6 ± 9.8	61.3 ± 9.8	61.6 ± 9.0	60.9 ± 9.4	61.2 ± 8.8	0.63
TP53 expression							0.0004
(-)	482 (57%)	187 (58%)	295 (56%)	187 (58%)	219 (52%)	160 (66%)	
(+)	362 (43%)	134 (42%)	228 (44%)	134 (42%)	206 (48%)	84 (34%)	

CIMP CpG island methylator phenotype, CRC colorectal cancer, HPPFS Health Professionals Follow-up Study, MSI microsatellite instability, MSS microsatellite stable, NHS Nurses' Health Study, SD standard deviation

Table 3
MGMT promoter methylation/loss of *MGMT* in colorectal cancer and patient mortality

	Total <i>n</i>	Colorectal cancer-specific mortality			Overall mortality		
		Deaths/person-years	Univariate HR (95% CI)	Multivariate HR (95% CI)	Deaths/person-years	Univariate HR (95% CI)	Multivariate HR (95% CI)
<i>Colorectal cancer</i>							
<i>MGMT</i> promoter							
Unmethylated	530	148/4,996	1 (referent)	1 (referent)	256/4,996	1 (referent)	1 (referent)
Methylated	325	86/3,002	0.95 (0.73–1.24)	1.03 (0.79–1.36)	159/3,002	1.03 (0.85–1.26)	1.08 (0.88–1.32)
<i>MGMT</i>							
Expressed	425	116/3,930	1 (referent)	1 (referent)	200/3,930	1 (referent)	1 (referent)
Lost	247	58/2,450	0.83 (0.61–1.14)	1.08 (0.85–1.37)	116/2,450	0.94 (0.75–1.18)	1.11 (0.87–1.41)
<i>Colon cancer</i>							
<i>MGMT</i> promoter							
Unmethylated	407	115/3,807	1 (referent)	1 (referent)	199/3,832	1 (referent)	1 (referent)
Methylated	247	57/2,336	0.80 (0.58–1.09)	0.85 (0.61–1.18)	118/2,354	0.96 (0.77–1.21)	1.00 (0.79–1.26)
<i>MGMT</i>							
Expressed	322	87/2,993	1 (referent)	1 (referent)	151/2,993	1 (referent)	1 (referent)
Lost	204	47/2,020	0.82 (0.58–1.17)	1.03 (0.71–1.49)	97/2,020	0.96 (0.74–1.24)	1.12 (0.86–1.46)
<i>Rectal cancer</i>							
<i>MGMT</i> promoter							
Unmethylated	117	31/1,129	1 (referent)	1 (referent)	53/1,129	1 (referent)	1 (referent)
Methylated	75	27/652	1.47 (0.87–2.46)	1.37 (0.79–2.36)	38/652	1.24 (0.82–1.89)	1.17 (0.75–1.84)
<i>MGMT</i>							
Expressed	100	27/920	1 (referent)	1 (referent)	46/920	1 (referent)	1 (referent)
Lost	40	9/416	0.77 (0.36–1.64)	0.96 (0.41–2.27)	16/416	0.77 (0.44–1.36)	1.05 (0.57–1.93)

The multivariate, stage-matched (stratified) Cox regression model initially included the *MGMT* promoter methylation or loss of *MGMT* variable, sex, age at diagnosis, year of diagnosis, tumor location, obesity, family history of colorectal cancer, tumor grade, CIMP, MSI, *BRAF*, and LINE-1 methylation. A backward elimination with threshold of $p = 0.20$ was used to select variables in the final models. CI confidence interval, HR hazard ratio